The Financial Times: Psychedelics are the Latest Employee Health Benefit

Summary: The Financial Times explores how ketamine-assisted therapy is gaining popularity with business leaders and the workplace as a viable health benefit for employees.

MAPS Justice, Equity, Diversity and Inclusion Officer Steven Huang mentions, “Making psychedelic therapy an employee benefit ‘solves a lot of the issues’ that come with accessibility, affordability, and the stigma attached to psychedelics as a medical treatment.”

Originally appearing here (Archived)